Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label D-1553 in KRAS G12C-mutant advanced or metastatic solid tumors
jRCT2031220006Phase 1Completed
- Sponsor
- InventisBio
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of garsorasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and pancreatic cancer (PC) (2 cohorts), sponsored by InventisBio. Primary endpoints: Adverse events and Dose-limiting toxicities. Started May 2022; status: completed.
02
Drugs
garsorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031220006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220006.